Cannabics Pharmaceuticals, Inc. (CNBX)

download

Cannabics Pharmaceuticals, Inc is a biotech company that produces proprietary technologies for medical cannabis therapies.

The company’s flagship product is the Cannabics SR, a sustained release cannabis capsule to provide palliative care to cancer patients. Using a patented formulation, Cannabics SR capsules contain a pure concentrate of cannabinoids from cannabis strains which the company itself selects and breeds. Each capsule is designed to provide 10-12 hours of therapeutic effects, thus allowing for a once-a-day dosage.

Other products in the company’s line are Cannabics IN, a capsule for dry powder inhalers, and Cannabics VP, a condensed pill for standard vaporizers. As of 2013, the company’s products are circulating through five Israel hospitals. It is noted that Israel permits medical marijuana use for patients with cancer and pain-related illnesses.

Cannabics Pharmaceuticals is based in Bethesda, Maryland. According to the company website, it is developing advanced cannabinoid-based therapies through its research and development arm in Israel. It is also collaborating with medical centers in Israel, the US (including states like Colorado and California), and Europe (including countries like Spain, Czech Republic, and the Netherlands) to launch clinical studies on their products.

Cannabics Pharmaceuticals, Inc is a fairly new name in the marijuana industry. It is a subsidiary of Cannabics, Inc, which was founded in 2012 by researchers in molecular biology, pharmacology, and cancer research. The pharmaceuticals company was also formerly known as Thrust Energy Corp until 2011, and as American Mining Corporation just until June 2014.

The company is currently traded in OTC markets as CNBX, with a market cap of USD 32.7 M. Its key executives are Dr. Zohar Koren, Co-founder and CEO; Dr. Eyal Ballan, Co-founder and CTO; and Itamar Borochov, VP of Marketing.


Yahoo! Finance: CNBX News

Latest Financial News for CNBX

/C O R R E C T I O N -- Cannabics Pharmaceuticals Inc./

In the news release, Cannabics Pharmaceuticals Appoints Two Independent Directors, issued June 25, 2019 by Cannabics Pharmaceuticals Inc. over PR Newswire, we are advised by the company that the 5th paragraph, 1st sentence, should read "Mr. Ballan served as Senior Executive Vice President and General Counsel at Gazit Globe, a Tel Aviv Stock Exchange listed company that is part of the TA-35 and Real-Estate 15 indexes in Israel." rather than as originally issued inadvertently. TEL AVIV, Israel and BETHESDA, Maryland, June 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has appointed two new independent directors to its board of directors, Dr. Estery Giloz-Ran and Eran Ballan, Esq.

Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada

TEL AVIV, Israel and BETHESDA, Maryland, June 4, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be participating at the LIFT & Co. Conference at the Metro Toronto Convention Centre in Toronto, Canada. "This year's conference in Toronto is exciting because it is the largest premier industry business conference event in Canada," stated Mr. Barad.

Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California

TEL AVIV, ISRAEL and BETHESDA, MD / ACCESSWIRE / May 30, 2019 / Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4 at 11:20AM PST at the Luxe Sunset Hotel in Bel Air, California. Mr. Eyal Barad (CEO of Cannabics Pharmaceuticals) will be presenting and meeting with investors. "This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges," stated Chris Lahiji, President at LD Micro.

Cannabics Pharmaceuticals' CEO to Present at the Planet MicroCap Conference in Las Vegas and at the ThinkEquity Conference in New York City

TEL AVIV, Israel and BETHESDA, Maryland, April 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, CEO, is scheduled to present at the Planet Microcap Conference in Las Vegas, Nevada, being held at the Bally's Hotel, and at the ThinkEquity Conference in New York City being held at The Mandarin Oriental Hotel. Mr. Barad is scheduled to present at the Planet MicroCap conference in Las Vegas at 2pm Pacific Time on May 1, 2019. Mr. Barad will also be speaking at the ThinkEquity conference, at 2pm Eastern Time, on May 2, 2019.

Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies

TEL AVIV, Israel and BETHESDA, Maryland, April 17, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has obtained approval for a nationwide Israeli multisite clinical study on the antitumor properties of cannabinoid compounds on primary cancer biopsies. The apoptotic/cytotoxic effects of a multitude of cannabinoid extracts will be evaluated via Cannabics' high throughput screening platform. Dr. Eyal Ballan, CTO and Co-Founder of Cannabics, said: "We believe this is a quantum leap for the research on the biology of cancer and cannabinoids.